Boehringer Ingelheim Presents Results of Gilotrif (afatinib) for NSCLC at IASLC NACLC 2020

 Boehringer Ingelheim Presents Results of Gilotrif (afatinib) for NSCLC at IASLC NACLC 2020

Boehringer Ingelheim Presents Results of Gilotrif (afatinib) for NSCLC at IASLC NACLC 2020

Shots:

  • Real-world study shows the effectiveness and safety of 2L Gilotrif following 1L IO plus CT in the treatment of squamous cell carcinoma of the lung
  • Results: Median overall TOT for patients who received 2L afatinib & CT (7.3mos. & 4.2mos.); the incidence of irAEs occurred in 6 patients while no reported irAES in the chemotherapy cohort.
  • Separate data presented indicate Gilotrif activity in TKI-naïve patients with G719X/L861Q/S768I non-resistant EGFR mutation-positive NSCLC. Gilotrif is indicated for metastatic NSCLC whose tumors have non-resistant EGFR mutations and for advanced squamous cell carcinoma of the lung, progressed after treatment with platinum-based CT

    Click here to­ read the full press release/ article | Ref: PRNewswire | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post